Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Obesity01:24

Obesity

1.6K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

372
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
372
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

445
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
445
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

330
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
330
Bulimia Nervosa01:30

Bulimia Nervosa

1.1K
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
1.1K
Binge Eating Disorders01:23

Binge Eating Disorders

832
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
832

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

New thoughts on managing obesity.

Gut·2004
Same author

Cardiovascular risks in obesity.

Journal of endocrinological investigation·2003
Same author

A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy.

Journal of the peripheral nervous system : JPNS·2002
Same author

Reply: Is obesity a disease?

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity·2001
Same author

Dose-response issues concerning physical activity and health: an evidence-based symposium.

Medicine and science in sports and exercise·2001
Same author

Evidence that single nucleotide polymorphism in the uncoupling protein 3 (UCP3) gene influences fat distribution in women of European and Asian origin.

Diabetologia·2001

関連する実験動画

Updated: May 5, 2026

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

13.7K

医学的な問題としての肥満

P G Kopelman1

  • 1St Bartholomew's & The Royal London School of Medicine, Queen Mary & Westfield College, UK. P.G.Kopelman@mds.qmw.ac.uk

Nature
|April 15, 2000
PubMed
まとめ

肥満は,世界的な健康危機として増大しており,病気の主な原因として栄養不足や感染症を上回っています. 糖尿病,心臓病,癌などの深刻な疾患に関連しており,緊急の注意が必要です.

科学分野:

  • 公衆衛生は公衆衛生である.
  • エピデミオロジー エピデミオロジー
  • メタボリック障害 メタボリック障害

背景:

  • 肥満は重要な世界的な健康問題であり,世界中でますます蔓延しています.
  • 糖尿病,冠動脈疾患,がん,睡眠呼吸障害を含む重篤な健康状態と関連しています.
  • 体重指数 (BMI) を用いた伝統的な定義は,健康上のリスク,特に腹内脂肪に関連するリスクを完全に捉えていません.

研究 の 目的:

  • 肥満の世界的な流行が拡大していることを強調するためです.
  • 肥満の多面的な健康上の影響を強調し,美容的な懸念を超えて.
  • 大規模な公衆衛生上の脅威である肥満に対処する必要性を強調する.

主な方法:

  • 肥満の流行に関する現在の疫学データのレビュー.
  • 肥満と主要な非伝染性疾患との間の確立された関連性の分析.
  • 肥満の流行に寄与するエチオロギー的要因の議論.

主要な成果:

  • 肥満は,世界的な罹病率と死亡率の主な原因として浮上しています.
  • 肥満と慢性疾患の発症との間に強い相関関係がある.
  • 遺伝的傾向,高カロリー食品へのアクセスの増加,身体活動の減少などの要因が,流行を駆り立てている.

さらに関連する動画

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.8K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

関連する実験動画

Last Updated: May 5, 2026

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

13.7K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.8K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

結論:

  • 肥満は,世界的な健康に重大な影響を及ぼす複雑な流行病です.
  • それは,個々の化粧品の問題から,広範囲にわたる公衆衛生上の課題への視点の転換を必要とする.
  • 肥満の根本的な原因に対処することは,世界中の福祉を改善するために非常に重要です.